Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp (DH) provides actionable healthcare commercial data through its SaaS platform, empowering strategic decisions across the $4 trillion U.S. healthcare sector. This news hub delivers verified updates about DH's operational developments, financial milestones, and market leadership.
Key resources include: Earnings call summaries, product enhancement announcements, executive leadership changes, and partnership disclosures. Investors gain insights into recurring revenue trends while healthcare professionals track innovations in provider analytics and predictive modeling tools.
All content undergoes strict editorial review using primary sources including SEC filings and official company communications. Bookmark this page for real-time updates on DH's expanding data ecosystem covering 2.7M+ healthcare providers and 10K+ technology installations.
Definitive Healthcare (Nasdaq: DH) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $60.0M (down 4% YoY). Net loss was $(17.8)M; prior-year Q3 included a $228.2M goodwill impairment. Adjusted net income was $9.7M and Adjusted EBITDA was $18.9M (32% of revenue). Operating cash flow was $15.7M and unlevered free cash flow was $17.9M. Management said Q3 results met or exceeded guidance, noting a $2M Adjusted EBITDA beat and improvements in new-logo production and retention.
Outlook: Q4 2025 revenue guidance of $59.0–$60.0M; full-year 2025 revenue raised to $239.0–$240.0M (bottom end +$2.0M); full-year Adjusted EBITDA expected $68.0–$69.0M.
Definitive Healthcare (Nasdaq: DH) will report third quarter results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.
The company will host a conference call and webcast on that date at 5:00 PM ET / 2:00 PM PT. A live audio webcast will be available on the company investor relations site at https://ir.definitivehc.com/. Live dial-in numbers are 877-358-7298 (domestic) and +1-848-488-9244 (international).
A replay will be available through December 6, 2025 at 800-645-7964 or 757-849-6722 using passcode 1765#.
Definitive Healthcare (NASDAQ:DH), a healthcare commercial intelligence company, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. CEO Kevin Coop and CFO Casey Heller will deliver a presentation on Tuesday, September 9, 2025, at 9:15 a.m. ET.
Investors can access a live webcast of the presentation through the Events section of Definitive Healthcare's investor relations website at ir.definitivehc.com. A replay will be available for a limited time after the event.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence leader, reported mixed Q2 2025 financial results. Revenue declined 5% year-over-year to $60.8 million, while net loss improved to $(9.3) million from $(306.2) million in Q2 2024. Adjusted EBITDA was $18.7 million, representing a 31% margin.
The company secured notable customer wins, including a healthcare revenue cycle management firm and a returning digital health organization. Based on H1 2025 progress, management raised guidance, projecting full-year 2025 revenue of $237.0-$240.0 million and adjusted EBITDA of $64.0-$67.0 million with 27-28% margins.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence leader, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025 after market close.
The company will host a conference call and webcast at 5:00 PM ET. Investors can access the live webcast through the company's IR website, or join via phone using the dial-in numbers: 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be available until September 6, 2025.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence company, announced inducement grants for two newly hired senior executives. The company's Human Capital Management and Compensation Committee has awarded 421,349 time-based restricted stock units (RSUs) each to Jeannine Lombardi, the new Chief Human Resource Officer, and Jonathan Paris, the new Chief Legal Officer.
The RSUs were granted on July 1, 2025, under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan. The vesting schedule includes 25% vesting on July 1, 2026, followed by quarterly installments of 6.25% over the subsequent three years, subject to continued employment.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence leader, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results.
Investors can access the live audio webcast on the company's IR website at https://ir.definitivehc.com/. A dial-in option is available at 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be accessible through June 7, 2025, using 800-645-7964 (domestic) or 757-849-6722 (international) with passcode 1765#.
Definitive Healthcare (Nasdaq: DH) has announced the granting of inducement awards to its newly hired senior leader. The company's Human Capital Management and Compensation Committee approved inducement awards for Jeff Moyer, who joins as SVP of Growth and Sales Operations.
The awards include 364,432 time-based restricted stock units (RSUs), effective April 3, 2025. The RSUs will vest according to the following schedule: 25% on April 1, 2026, with the remaining amount vesting in quarterly installments of 6.25% over the subsequent three years. These awards were granted under Definitive Healthcare's 2023 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
